Recent studies have emerged to reveal the pivotal roles of mechanistic target of rapamycin (mTOR) signaling not only in the maintenance of the physiological functions of renal cells but also in the pathogenesis of renal cell dysfunctions and kidney diseases. We introduce the current understanding of mTOR signaling, and its crucial roles in glomerular epithelial cell biology and the pathophysiology related to kidney diseases.
INTRODUCTION
Differentiated podocytes possess elaborated foot processes that form a functional filtration barrier in glomeruli [1] . Because active filtration requires constant maintenance and renewal of the filtration unit, glomerular podocytes may represent a key site of mechanical breakdown in renal failure. One of the major reasons for the vulnerability of podocytes as a filter is that these highly differentiated epithelial cells lack replicative capacity [2] . Various genetic and environmental insults cause podocyte injuries, including podocyte foot process effacement and podocyte loss because of cell death or detachment from the glomerular basement membrane [3] . Such podocyte injuries lead to the generation of proteinuria and glomerular dysfunction. In this regard, many glomerular disorders that generate proteinuria constitute a spectrum of podocytopathies in which the progression of glomerular dysfunction is often associated with net depletion of podocytes from glomerular tufts [4] .
Recent studies suggest that changes in podocyte mass/volume/size in response to stresses may trigger its injury and cause death or detachment from the glomerular basement membrane (GBM) [1, 3, 5] . In recent years, studies have begun to reveal the molecular mechanisms underlying abnormal cell growth and metabolism that leads to the dysfunction of podocytes [6] [7] [8] [9] [10] [11] [12] . Among these, the mechanistic target of rapamycin (mTOR) signaling pathway has been recognized as a key regulatory pathway for normal podocyte function, and its dysregulation under disease conditions such as diabetes leads to their dysfunction and glomerulopathy [11, 12] .
Mechanistic target of rapamycin complexes and the effect of rapamycin
Two distinct functional mTOR containing protein complexes have been identified, termed mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [13] [14] [15] [16] [17] . mTORC1 is comprised of mTOR, Raptor, PRAS40, mLST8, and Deptor. Raptor is an essential component of mTORC1, functioning as a scaffold for specific mTORC1 substrates such as S6K1 and 4EBP1 [18] [19] [20] . Raptor also plays an essential role in tethering mTORC1 to the lysosomal membrane for its activation [21, 22] .
In contrast, mTORC2 is comprised of mTOR, Rictor, Sin1, mLST8, Deptor, and Protor. Deletion of Rictor, Sin1, or mLST8 abolishes mTORC2 activity as the phosphorylation of mTORC2 substrates such as Akt and SGK1 is largely abolished [14, 17, [23] [24] [25] .
Rapamycin is a potent and specific inhibitor of mTORC1. After associating with FK-506-binding protein 12 (FKBP12), the rapamycin-FKBP12 complex directly binds to the FKBP12-rapamycin-binding (FRB) domain of mTOR kinase in mTORC1 [26] and allosterically inhibits mTOR kinase activity by blocking the accessibility of substrates to the active site of mTOR kinase [27] . In contrast to its specific effect on mTORC1, rapamycin has little effect on mTOR kinase activity in mTORC2. A recent cryo-EM study of mTORC2 demonstrated that Rictor, an essential mTORC2 component, masks the FRB domain of mTOR kinase of mTORC2 [28 & ]. These suggest that the rapamycin-FKBP12 complex may not be able to access the FRB domain to inhibit mTOR kinase activity once mTORC2 is formed. Interestingly, however, it has been reported that prolonged rapamycin treatment attenuates the formation of mTORC2, thereby preventing mTORC2 from phosphorylating its substrates [29] . These observations suggest that the rapamycin-FKBP12 complex may gain access to newly synthesized mTOR and prevent mTOR from forming functional mTORC2.
Downstream of mTORC1 and mTORC2
mTORC1 functions as a master regulator of cell growth and proliferation by phosphorylating and regulating multiple downstream effectors, which are involved in protein and lipid biosynthesis, glucose metabolism, cellular organelle formation, and protein degradation [30] (Fig. 1 ). Among the group of mTORC1 substrates, S6K1 and 4EBP1 are the best characterized substrates. mTORC1 directly phosphorylates and activates S6K1 [31] [32] [33] . Active S6K1 promotes mRNA translation at several different steps including mRNA splicing, translation initiation, and elongation, by phosphorylating key translational regulators such as sker, eIF4B, and eEF2K [34] . Interestingly, S6K1 activation negatively feeds back to the PI3K-Akt pathway. By phosphorylating and destabilizing insulin receptor substrates (IRS1/2), mTORC1-mediated S6K1 activation inhibits growth factor-induced PI3K activation [35] [36] [37] .
4EBP1 is also a well-characterized mTORC1 substrate. In the absence of mTORC1 activity, hypophosphorylated 4EBP1 binds to eIF4E, a 5 0 Cap binding protein, to inhibit its interaction with eIF4G1 to form an active initiation complex, thereby suppressing Cap-dependent translation initiation. Phosphorylation of 4EBP1 by mTORC1 leads to its dissociation from eIF4E, which is a critical step of translation initiation [38, 39] .
Autophagy is an evolutionarily conserved major catabolic process in which unnecessary, dysfunctional, or toxic cellular materials are captured and delivered by double-membrane vesicles (i.e., autophagosomes) to the lysosome for degradation [40] [41] [42] . This process is essential for maintaining cellular energy and nutrient levels under metabolic stress conditions such as starvation. mTORC1 functions as a major suppressor for autophagy by phosphorylating and inhibiting Ulk1, a kinase required for the initiation of autophagy [43] [44] [45] .
mTORC2 directly phosphorylates and stimulates AGC kinases such as Akt, PKC, and SGK1 [14, [46] [47] [48] [49] (Fig. 1 ). mTORC2-dependent Akt phosphorylation and activation play important roles in stimulating glucose uptake, viability, and cytoskeletal organization of cells. For actin remodeling, two small GTPases, RhoA and Rac1, have been reported to play critical roles in cytoskeleton reorganization downstream of mTORC2. Deletion of mTORC2 disrupts formation of the actin cytoskeleton, which is rescued by expression of the constitutively active form of Rac1 or RhoA. Although the precise molecular mechanisms remain elusive, mTORC2 stimulates GTP-loading of Rac1 and RhoA, indicating that mTORC2 functions as an important activator for both Rac1 and RhoA in cytoskeleton formation and organization [14] .
KEY POINTS
mTORC1 is essential for the physiologic functions of podocytes. However, aberrant activation of mTORC1 causes podocyte injuries, which is one of the important pathomechanisms of glomerulopathies, including diabetic nephropathy. mTORC2 is also important for podocyte functions under stress conditions. The balance of cellular mTORC1 and mTORC2 activity is important for maintaining the functions of differentiated podocytes.
An effective treatment for mTORC1-associated podocyte dysfunction may require the attenuation of mTORC1 activity in the setting of both an intact mTORC2-Akt pathway and normal basal mTORC1 activity in order to preserve physiologic podocyte functions.
Upstream of mTORC1 and mTORC2
Growth factors are activators for both mTORC1 and mTORC2 in a manner dependent on their activation of the PI3K pathway. In the case of mTORC1, PI3Kactivated Akt phosphorylates and inactivates TSC2, an essential component of the tuberous sclerosis complex (TSC), which functions as a GTPase activating protein (GAP) for Rheb [50] [51] [52] . Rheb is a Ras-related small GTPase, which directly and potently activates mTORC1 [53, 54] . Ablation of TSC2 causes constitutive mTORC1 activation even in the absence of growth factors. Thus, by inactivating the upstream negative regulator, growth factor signaling leads to mTORC1 activation. Interestingly, both the Rheb small GTPase and the TSC complex are mainly expressed on lysosomes
]. These observations suggest that growth factor-dependent mTORC1 activation mainly occurs on the lysosomal membrane. To stimulate mTORC1 activity on the lysosomal membrane, two lysosome-associated protein complexes, Rags, and their activator, Ragulator, play important roles in recruiting mTORC1 to the lysosomal membrane in response to amino acids [21, 22, 58] . Rag is an evolutionarily conserved small GTPase and consists of four isoforms (RagA/B/C/D) in mammals. RagA or B forms an obligate heterodimer with Rag C or D [59] [60] [61] . Ragulator is a pentameric protein complex, consisting of five subunits, p18 (LAMTOR1), p14, MP1, HBXIP, and C7orf59 [21, 58] . Importantly, Ragulator functions as both a scaffold and a guanine nucleotide exchange factor (GEF) for RagA/B, which directly recruits mTORC1 to the lysosomal membrane [58] . A common picture arising from these recent studies is that amino acids play an essential role in recruiting mTORC1 to the late endosome/lysosome membranes in which Rheb directly activates mTORC1. The current model explains why both growth factors and amino acids are required for mTORC1 activity.
The molecular mechanisms underlying growth factor-dependent mTORC2 activation remain obscure. A recently study suggests that ribosomes play important roles in growth factor-mediated mTORC2 activation. mTORC2 physically interacts with some of the ribosome subunits, and this binding is enhanced by insulin-derived PI3K activity. Inhibiting intact ribosome biogenesis by knockdown of a component of the large or small ribosome subunit, but not translational activity, reduces mTORC2 activity [62] . Thus, rather than ongoing mRNA translation, it is the amount of cellular ribosomes that defines a key determinant for mTORC2 activity in cells.
mTORC1 in podocytes
Interestingly, mTORC1 is hyperactivated in podocytes in both type 1 and type 2 diabetic mice and patients with type 2 diabetes [11, 12] . Rapamycin treatment, which blocks mTORC1 activity, prevents the development of diabetic nephropathy in animal models, suggesting that enhanced mTORC1 activity in podocytes may have pathologic roles in the onset/development of diabetic nephropathy. To further reveal the pathologic roles of mTORC1 activation in podocyte dysfunction, podocyte-specific TSC1 knockout (podo-TSC1 knockout), where podocytes display aberrant mTORC1 activation, was generated in a nondiabetic mouse background [11] . Importantly, podo-TSC1 knockout mice recapitulate many pathologic phenotypes seen in diabetic nephropathy including podocyte loss, glomerular basement membrane thickening, mesangial expansion, and proteinuria. mTORC1 hyperactivation causes mislocalization of slit diaphragm proteins and induces endoplasmic reticulum stress and epithelial-mesenchymal transition (EMT)-like phenotypic changes, which may compromise the integrity of podocytes. Furthermore, in both streptozotocin-induced type 1 diabetic mice and obesity-related type 2 diabetic mice (db/db mice), partial reduction of mTORC1 activity specifically in podocytes by the deletion of one allele of the RAPTOR gene effectively attenuates the onset or development of diabetic nephropathy [11, 12] . These observations indicate that the aberrant activation of mTORC1 is causative for podocyte injury and the onset/development of diabetic nephropathy ( Fig. 2) .
It is noteworthy that complete ablation of mTORC1 activity in podocytes in podo-Raptor knockout mice leads to early onset of proteinuria [11, 12] . These observations imply that although excessive mTORC1 activation is detrimental, basal mTORC1 activity is required for maintaining the physiologic functions of podocytes. In particular, ablation of Raptor in podocytes during embryonic stages leads to severe proteinuria, whereas Raptor deletion in podocytes of mature animals shows moderate proteinuria. These findings suggest that basal mTORC1 activity is particularly important during the period of podocyte differentiation, growth, and functional development (Fig. 2) .
As a terminally differentiated cell, podocytes lose their capability for replication once they migrate from the parietal epithelium to the surface of the glomerular tuft, where they cover the filtration area during the capillary loop stage of kidney development. However, during postnatal development, the glomerular tuft volume continues to increase because of increased glomerular capillary number and surface area [63, 64] . In order to cope with the enlarging glomerular tuft, podocytes need to increase their mass (hypertrophy) to cover the enlarged filtration area [65] . In this regard, mTORC1 activity in podocytes may play an important role for their postnatal growth (Fig. 2) . Insufficient mTORC1 activity may inhibit the podocyte growth that is needed to accommodate the enlarged filtration area and cause the production of proteinuria and the ]. In line with this notion, Fukuda et al. have developed podocyte-specific AA-4EBP1 transgenic rats in which podocytes have decreased mTORC1-dependent translational activity. AA-4EBP1 is a nonphosphorylatable mutant of the mTORC1 substrate 4EBP1 that interferes with mTORC1-dependent translation initiation. In this model, proteinuria and glomerulosclerosis in podocyte-specific AA-4E-BP1 transgenic rats were linearly correlated with increasing body weight and glomerular volume. The histology analysis revealed bare areas of the glomerular basement membrane because of the detachment of podocyte foot processes, followed by adhesion of glomerular tufts to the Bowman's capsule [66 && ]. This study indicated that mTORC1-dependent translation sets the threshold for the adaptive growth capacity of podocytes and provided a plausible explanation for the high incidence of FSGS in fast growing young adults and in the obese population. In addition, these observations also support the idea that ablation of mTORC1 activity in podocytes may restrict their capability for adaptive growth, which is required during the development of the glomerulus or under certain pathologic conditions including hypertension, diabetes, and remnant kidney.
mTORC2 in podocytes
In contrast to mTORC1 inhibition in podo-Raptor knockout mice, podo-Rictor knockout mice in which mTORC2 activity is abolished in podocytes did not display any obvious clinical, histological, or ultrastructural abnormalities in their glomeruli, even in a long-term follow up study. However, mTORC2 deletion decreased the ability of podocytes to maintain normal function under stress conditions. Upon BSA overloading stress, levels of proteinuria were significantly increased in podo-Rictor knockout mice compared with wild-type littermates, suggesting that the function of mTORC2 in podocytes is required for their adaptation under certain stress conditions. Moreover, additional Rictor ablation in podo-Raptor knockout mice (podo-Raptor/Rictor double knockout mice) exacerbated proteinuria levels and glomerular dysfunction [12] . These observations indicate that in a sensitized mTORC1 mutant background in podocytes, mTORC2 may exert important roles in maintaining the functional structure and viability of podocytes.
Given the important role of mTORC2 in cytoskeleton reorganization [14] and the essential role of actin cytoskeleton in podocyte integrity (reviewed by [67] ), the activity of mTORC2 may be needed to preserve actin reorganization in response to stress. It should be noted that the activity of Akt, which positively regulates cell survival and reorganization of the cytoskeleton, is not completely abolished by the deletion of mTORC2 in many different types of cells including podocytes. This might be one of the reasons why podo-Rictor knockout mice appear superficially wild-type under normal conditions. In line with the above observations, Canaud et al. [68 && ] demonstrated that the activity of Akt2 in podocytes is essential for maintaining their physiologic functions as podocyte-specific Akt2 knockout mice show considerable podocyte injury and glomerular dysfunction.
In accordance with the notion that Akt2 activity is essential for podocyte viability, an earlier study suggested that the intact insulin signaling pathway in podocytes is pivotal for maintaining podocyte and glomerular functions during normal kidney development. Welsh et al. [69] demonstrated that podocyte-specific insulin receptor knockout mice (podo-IR knockout) display proteinuria from 5 weeks of age and develop glomerulosclerosis by week 8 of development. Loss of cytoskeletal architecture in podocyte foot processes was the earliest alteration detected in podo-IR knockout mice [69] . Taken together, these recent studies suggest that aberrant activation of mTORC1 in podocytes is likely to be a first step in the pathological signaling that occurs under diabetic conditions, leading to aberrant growth phenotypes including podocyte and glomerular hypertrophy. Simultaneously, hyperactivation of mTORC1 causes a reduction of the IR-PI3K-Akt pathway in podocytes and leads to the impairment of actin cytoskeletal reorganization and the loss of podocyte viability.
Rapamycin analogs such as sirolimus are widely used in renal transplant patients as an immune suppressive agent. Despite the beneficial effects of rapamycin on experimental diabetic nephropathy in animal models, considerable clinical evidence suggests that sirolimus often induces albuminuria in renal transplant recipients with compromised renal function [70] [71] [72] , which may limit the clinical use of sirolimus in treating any glomerular diseases, including diabetic nephropathy. Considering that basal mTORC1 activity is required for maintaining normal podocyte functions, complete blockade of mTORC1 activity with long-term sirolimus treatment may evoke adverse outcomes on podocytes. More importantly, prolonged sirolimus treatment also prevents the assembly of newly formed mTORC2 [29] , which plays important roles in the activation of Akt2. By reducing both cellular mTORC1 and mTORC2 activity, long-term sirolimus treatment may compromise the integrity and physiological functions of podocytes under stress conditions.
CONCLUSION
Taken together, an effective treatment for mTORC1associated podocyte dysfunction may require the attenuation of mTORC1 activity in the setting of both an intact mTORC2-Akt pathway and normal basal mTORC1 activity in order to preserve physiologic podocyte functions. One plausible, but promising approach, may be to target the nutrientsensing mechanism for mTORC1 activation. Amino acids, especially leucine and glutamine, are key nutrients for spatial recruitment and activation of mTORC1 on lysosomal membranes [73, 74] . Unlike the growth factor-PI3K pathway, spatial regulation of mTOR by amino acids is specific to mTORC1 but not mTORC2. Furthermore, a recent study suggested that leucine and glutamine use distinct mechanisms to recruit mTORC1 to the lysosomal membrane [75] . For instance, disruption of the Ragulator-Rag system abolishes leucine-dependent lysosomal localization whereas glutamine is still able to recruit mTORC1 to lysosomes through an Arf1-dependent manner. Lack of one of these mechanisms significantly reduces lysosomal mTORC1 localization but it does not completely eliminate mTORC1 localization on lysosomes, thus preserving some, albeit lower, mTORC1 activity in these cells. In addition, hypothetically, lower mTORC1 activity in podocytes may sensitize the growth factor-PI3-Akt pathway, which is essential for the integrity of podocytes. Therefore, targeting these amino acid sensing mechanisms may be a promising approach to reduce but not abolish cellular mTORC1 activity without inhibiting the PI3K-mTORC2-Akt pathway in podocytes.
With the notion that the mTOR complexes exist at the nexus of many signaling cascades and have numerous crosstalk with other signaling pathways, such as the Notch and Wnt pathways, it is likely that multiple pathways may coordinately work to maintain a proper balance of mTOR activity, which is essential for the normal functions of podocytes. Thus, it is important to identify molecular mechanisms underlying the dysregulation of mTOR signaling under different stress and disease conditions, including diabetes and obesity. The elucidation of the molecular mechanisms by which mTORC1 or mTORC2 participates in the functions of podocytes and other renal cells will be helpful in developing more precise strategies for intervening in specific kidney diseases.
